Altropane 123I - GE Healthcare
Alternative Names: Altropane (123I) Injection; Dopamine transporter imaging radiopharmaceutical - GE Healthcare/ LikeMindsLatest Information Update: 27 Apr 2023
At a glance
- Originator LikeMinds
- Developer GE Healthcare
- Class Contrast media; Esters; Fluorobenzenes; Iodine radioisotopes; Radiopharmaceutical diagnostics; Small molecules; Tropanes
- Mechanism of Action Single-photon emission-computed tomography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Parkinson's disease
Most Recent Events
- 19 Apr 2023 Phase-II clinical trials in Parkinson's disease (Diagnosis) in USA (IV) (NCT05636852)
- 05 Dec 2022 GE Healthcare plans phase II trial in Parkinson's disease (Diagnosis) (IV) in February 2023 (NCT05636852)
- 28 Mar 2022 GE Healthcare plans a next-stage clinical trial in Parkinsonian disorders (Diagnosis) in USA